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Acute and chronic respiratory infections are the leading causes of morbidity and mortality
worldwide [1]. A better understanding of the epidemiology, pathophysiologic mechanisms and
potential new treatments of chronic respiratory infections is one of the main issues in the management
of chronic respiratory infections.
In this special issue, 9 original research studies and 5 reviews have been published (see Table 1).
Table 1. Contributions to the special issue "Lung Diseases: Chronic Respiratory Infections".
Authors Title Type Key Messages
Douglas
JE et al. [2]
Taste Receptors Mediate Sinonasal
Immunity and Respiratory Disease
Review Upper airway epithelium bitter taste
receptors stimulation, specifically T2R38,
potentiate the local innate
immune response
Shiratori
B et al. [3]
Immunological Roles of Elevated
Plasma Levels of Matricellular
Proteins in Japanese Patients with
Pulmonary Tuberculosis
Original
Research
Matricellular proteins, including
osteopontin and galectin-9, seems to have
an immunoregulatory, rather than
inflammatory, effect in the context of
TB pathology
An J
et al. [4]
Polydeoxyribonucleotide ameliorates
lipopolysaccharide-induced lung
injury by inhibiting apoptotic cell
death in rats
Original
Research
In an animal model,
polydexyribonucleotide (PDRN)
demonstrated an anti-inflammatory effect,
decreasing inflammatory cytokines,
and suppressing apoptosis. Further
studies will address the possible use of
PDRN as a new treatment of lung injury.
Florence
JM
et al. [5]
Disrupting the Btk pathway
suppresses COPD-like lung
alterations in atherosclerosis prone
ApoE−/− mice following regular
exposure to cigarette smoking
Original
Research
Bruton’s tyrosine kinase (Btk) is involved
in the regulation of inflammatory
processes in the lungs by regulating the
expression of matrix metalloproteinase-9
in the alveolar compartment. In an animal
model, the pharmacological inhibition of
Btk showed protective effects in the lung
exposed to cigarette smoke
Lorè NI
et al. [6]
Synthesized heparan sulfate
competitors attenuate
Pseudomonas aeruginosa lung infection
Original
research
Competitors of heparan sulfate, N-acetyl
heparin and glycol-split heparin reduce
leukocyte recruitment and
cytokine/chemokine production in an
animal model of acute and chronic
P. aeruginosa pneumonia. In vitro data
suggest a reduction in biofilm formation
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Carnell SC
et al. [7]
Targeting the bacterial cytoskeleton
of the Burkholderia cepacia complex
for antimicrobial development: a
cautionary tale
Original
Research
Bacterial cytoskeleton destabilizing
compounds seem to be potentially
harmful in the treatment of
Burkholderia cepacia complexes as it
induces an increase in bacterial
virulence factors.
Bragonzi A
et al. [8]
Enviromental Burkholderia cenocepacia
strain enhances fitness by serial
passages during long-term chronic
airway infections in mice
Original
research
Multiple passages of
Burkholderia cenocepacia are associated
with an increased ability to induce
chronic lung infections in an animal
model with clones with high virulence
Bacci G
et al. [9]
A different microbiome gene
repertoire in the airways of cystic
fibrosis patients with severe lung
disease
Original
Research
Analysis of the microbiome in severe lung
disease of cystic fibrosis patients has
shown that there is an increase in
virulence- and resistance-related genes.
Everaerts S
et al. [10]
Aspergillus fumigatus detection and
risk factors in patients with
COPD–bronchiectasis overlap
Original
Research
Aspergillus fumigatus presence in the
airways is prevalent in COPD patients
with bronchiectasis, particularly in the
presence of steroid treatment
Maiz L
et al. [11]
Fungi in bronchiectasis: a concise
review
Review Candida albicans and Aspergillus fumigatus
appear to be the most prevalent fungi
isolated in bronchiectasis
Faverio P
et al. [12]
Characterizing non-tuberculous
Mycobacteria infections in
bronchiectasis
Original
Research
In a prospective, observational study of
261 adult bronchiectasis patients,
non-tuberculous mycobacteria (NTM)
infections have been evaluated. NTM
isolation seems to be a frequent event in
bronchiectasis patients. Cylindrical
bronchiectasis, a CT “tree-in-bud” pattern
and a history of weight loss are
parameters that might help to suspect the
occurrence of a NTM infection.
Maselli DJ
et al. [13]
Inhaled antibiotic therapy in chronic
respiratory disease
Review The review analyzes the evidence on the
use of inhaled antibiotics in patients with
cystic fibrosis, bronchiectasis and
non-tuberculous mycobacteria (NTM)
infections. Further studies are needed to
define the role of inhaled antibiotics.
Miravittles
M et al. [14]
Chronic respiratory infections in
patient with chronic obstructive
pulmonary disease: what is the role
of antibiotics?
Review Chronic infection is associated with
COPD exacerbations. Antibiotic use in
acute events is controversial but may be
important in patients with higher risk of
poor outcomes. Antibiotic prophylaxis
remains controversial
Fastrès A
et al. [15]
The lung microbiome in idiopathic
pulmonary fibrosis: a promising
approach for targeted therapies
Review The literature analysis seems to indicate
the need for clinical trials of long-term
antibiotherapy to see if can act as an
immunomodulator and an
antibioprophylaxis to prevent acute
exacerbations
The first group of articles analyzes different possible pathways of the immune and inflammatory
response, before proposing possible diagnostic and treatment interventions [2–5].
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Douglas et al. [2] analyzed the evidence from the literature on the enhancement of upper
respiratory innate immunity due to bitter taste receptors and the possible roles of individual taste
differences in the clinical management of patients with upper respiratory infections. The main bitter
taste receptor, T2R38, responds to bitter compounds produced by invading bacteria, which potentiates
the immunological response through the innate response. The authors suggest that the possible role
of bitter taste receptors could be a target for therapeutic interventions aimed to enhance the immune
response to bacteria.
The potential role of matricellular proteins as immunomodulators is addressed in the paper
by Shiratori et al., which analyzed the plasma levels in Japanese patients affected by pulmonary
tuberculosis or latent tuberculosis compared to healthy controls [3]. The correlations between
matricellular proteins, such as osteopontin, soluble CD44 and galectin-9, and severity scores seems to
indicate that these proteins can be predictors of tuberculosis-related inflammation and clinical severity.
The role of anti-inflammatory compounds in preventing lung injury was assessed in the original
research by An et al. [4]. In an animal model, using lipopolysaccharide (LPS) tracheal instillation,
the authors identified Polydexyribonucleotide (PDRN) as a potent agent for reducing the excessive
apoptosis that plays a key role in the progression of lung injury induced by LPS, suggesting that PDRN
should be evaluated as a potential therapeutic agent for the treatment of lung injuries.
The regulation of inflammatory processes in the lung through the new potential targets was
analyzed in the original research published by Florence et al. [5]. The authors demonstrate that Bruton’s
tyrosine kinase (Btk) and matrix metalloproteinase-9 (MMP-9) specific siRNA can down-regulate lung
inflammation in a mice model. Both Btk and specific inhibitors of MMP-9 are suggested as potential
therapeutic targets.
The second group of papers addresses the control of difficult-to-treat Gram-negative bacteria that
are associated with recurrent and/or persistent lung infections [6–9].
Chronic Pseudomonas aeruginosa infections are associated with high inflammation levels in the
airways and in the lung. Heparan sulfate competitors have been evaluated by Lorè et al. as possible
anti-inflammatory compounds [6]. The authors analyzed the efficacy of different heparan sulfate
competitors in reducing leukocyte recruitment, cytokine/chemokine production and bacterial burden
that is associated with acute and chronic Pseudomonas infections using both in vitro and in vivo models.
N-acetyl heparin and a glycol-split heparin resulted in decreased inflammation, biofilm formation
and bacterial burden, suggesting that these compounds can be novel therapeutic approaches for
Pseudomonas infections.
Burkholderia cepacia complex (BCC) is a difficult-to-treat group of opportunistic pathogens that
mainly affect cystic fibrosis and immunocompromised patients. Carnell et al. [7] analyzed the potential
antimicrobial efficacy and effect of a new antimicrobial compound S-(4-chlorobenzyl)isothiourea
hydrochloride (Q22) on the virulence-related traits of BCC bacteria. This drug is an inhibitor of one
cytoskeletal protein, which is namely the actin homolog MreB.
Unfortunately, Q22 appears to enhance the BCC virulence and proinflammatory potential in an
in vitro model. Moreover, in the in vivo model, exposure to Q22 seems to increase the level of resistance
to H2O2-induced oxidative stress by BCC strains and the compound was toxic to the mice.
Bragonzi et al. [8] reported the ability of a BCC Mex1 strain to rapidly establish respiratory
tract chronic infections in mice following serial passages. This capacity is apparently not related to
phenotypic and genetic changes, but is probably linked to an increased virulence.
Microbiome gene repertoire in the airways of cystic fibrosis patients with severe lung disease has
been evaluated by Bacci et al. [9]. Metagenomics investigation of the bacterial communities resulted
in the identification of a high prevalence of genes that have been related to antibiotic resistance and
virulence mechanisms in patients with more severe disease.
The third group of articles analyzed fungi and non-tuberculous mycobacteria (NTM)
epidemiology and potential new treatment approaches in patients with bronchiectasis and cystic
fibrosis [10–12]. Everaerts et al. reported the results of a study addressing the potential role of
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galactomannan detection in the induced sputum of COPD and COPD–bronchiectasis overlap patients
for the diagnosis of Aspergillus fumigatus infections [10]. Patients with COPD–bronchiectasis overlap
have a higher rate of positive results. The authors suggest that galactomannan detection in induced
sputum may provide a sensitive marker for Aspergillus fumigatus infections.
In the same line, Maiz et al., in a concise review, analyzed the role of fungal infections in
patients with bronchiectasis [11]. The authors discussed the problems related to the diagnosis,
epidemiology and clinical significance. Moreover, the need for further research into the lung
mycobiome and its interactions with viral and bacterial microbiota in the pathogenesis of bronchiectasis
was underlined.
In the last few years, an increasing interest in NTM pulmonary involvement has been reported
in different diseases [16]. Faverio et al. reported an observational, prospective study describing
the management, in real life, of NTM pulmonary infections in a cohort of 261 adult bronchiectasis
patients [12]. In 12% of these patients, a NTM pulmonary infection has been demonstrated with an
association with cylindrical bronchiectasis, a history of weight loss and a “tree-in-bud” radiological
pattern. Only 1/3 of these patients achieved culture conversion without recurrence. This study shows
a fairly high incidence of NTM infection and gives some insights on the possible clinical parameters
that are associated with an increased risk of NTM infection.
Inhaled antibiotic therapy in chronic respiratory diseases is another important topic analyzed in
this special issue [13,14]. Inhaled antibiotic therapy has many potential benefits in the management
of chronic respiratory infections, which are mainly related to the high concentration in the target
site, increasing the potential efficacy and reducing systemic exposure by minimizing the toxicity [17].
Maselli et al. reviewed the potential role of inhaled antibiotic treatment in patients with cystic fibrosis,
bronchiectasis and NTM pulmonary infections [13]. In cystic fibrosis, inhaled antibiotics have been
demonstrated to significantly improve the disease management by reducing exacerbations in addition
to improving lung function and quality of life [18].
Inhaled antibiotic treatment efficacy in bronchiectasis is still an open and challenging question.
No inhaled antibiotics have been approved in this indication even if the experts indicate that this
therapy is a treatment of choice for the management of chronic respiratory infections in these
patients [19].
Maselli et al. also analyzed the data on the use of this approach in NTM pulmonary infections,
reporting promising results of inhaled liposomal amikacin, which was recently confirmed by the FDA
approval of one formulation for human use [20].
COPD is another respiratory disease where antibiotics are largely used. Miravitlles et al. reviewed
the role of antibiotics in treating and preventing COPD exacerbations [14]. Antibiotics should be
reserved for the treatment of exacerbations of patients with severe disease and presenting a cluster of
symptoms, including increased sputum purulence and worsening dyspnea. Long-term preventive
therapy with antibiotics is controversial and should be used cautiously due to the potential side effects,
increase in resistance rate and microbiome alterations.
The microbiome is increasingly reported as a potential actor in the pathogenesis of idiopathic
pulmonary fibrosis [21]. In this special issue, Fastres et al. analyzed the potential role of the lung
microbiome as a therapeutic target in idiopathic pulmonary fibrosis [15]. The authors conclude
that antibiotic therapy, particularly long-term, may have a role in controlling exacerbations and
immunomodulating the inflammatory response.
In conclusion, I would like to thank all the authors who contributed to this Special Issue.
The articles that were published illustrate the advances in the research in chronic respiratory infections,
which provides important insights that will help all the clinicians in improving the diagnosis and
management of these important diseases.
Conflicts of Interest: The author declares no conflict of interest.
Int. J. Mol. Sci. 2018, 19, 3051 5 of 6
References
1. GBD 2015 LRI Collaborators: Estimates of the global, regional, and national morbidity, mortality,
and aetiologies of lower respiratory tract infections in 195 countries: A systematic analysis for the Global
Burden of Disease Study 2015. Lancet Infect. Dis. 2017, 17, 1133–1161. [CrossRef]
2. Douglas, J.; Cohen, N. Taste receptors mediate sinonasal immunity and respiratory disease. Int. J. Mol. Sci.
2017, 18, 437. [CrossRef] [PubMed]
3. Shiratori, B.; Zaho, J.; Okumura, M.; Chagan-Yasutan, H.; Yanai, H.; Mizuno, K.; Yoshiyama, T.; Idei, T.;
Ashino, Y.; Nakajima, C.; et al. Immunological Roles of Elevated Plasma Levels of Matricellular Proteins in
Japanese Patients with Pulmonary Tuberculosis. Int. J. Mol. Sci. 2017, 18, 19. [CrossRef] [PubMed]
4. An, J.; Park, S.; Ko, I.; Jin, J.; Hwang, L.; Ji, E.; Kim, S.; Kim, C.; Park, S.; Hwang, J.; et al.
Polydeoxyribonucleotide Ameliorates Lipopolysaccharide-Induced Lung Injury by Inhibiting Apoptotic
Cell Death in Rats. Int. J. Mol. Sci. 2017, 18, 1847. [CrossRef] [PubMed]
5. Florence, J.; Krupa, A.; Booshehri, L.; Gajewski, A.; Kurdowska, A. Disrupting the Btk Pathway Suppresses
COPD-Like Lung Alterations in Atherosclerosis Prone ApoE−/− Mice Following Regular Exposure to
Cigarette Smoke. Int. J. Mol. Sci. 2018, 19, 343. [CrossRef] [PubMed]
6. Lorè, N.; Veraldi, N.; Riva, C.; Sipione, B.; Spagnuolo, L.; De Fino, I.; Melessike, M.; Calzi, E.; Bragonzi, A.;
Naggi, A.; et al. Synthesized Heparan Sulfate Competitors Attenuate Pseudomonas aeruginosa Lung
Infection. Int. J. Mol. Sci. 2018, 19, 207. [CrossRef] [PubMed]
7. Carnell, S.; Perry, J.; Borthwick, L.; Vollmer, D.; Biboy, J.; Facchini, M.; Bragonzi, A.; Silipo, A.; Vergunst, A.;
Vollmer, W.; et al. Targeting the Bacterial Cytoskeleton of the Burkholderia cepacia Complex for Antimicrobial
Development: A. Cautionary Tale. Int. J. Mol. Sci. 2018, 19, 1604. [CrossRef] [PubMed]
8. Bragonzi, A.; Paroni, M.; Pirone, L.; Coladarci, I.; Ascenzioni, F.; Bevivino, A. Environmental Burkholderia
cenocepacia Strain Enhances Fitness by Serial Passages during Long-Term Chronic Airways Infection in
Mice. Int. J. Mol. Sci. 2017, 18, 2417. [CrossRef] [PubMed]
9. Bacci, G.; Mengoni, A.; Fiscarelli, E.; Segata, N.; Taccetti, G.; Dolce, D.; Paganin, P.; Morelli, P.; Tuccio, V.;
De Alessandri, A.; et al. A Different Microbiome Gene Repertoire in the Airways of Cystic Fibrosis Patients
with Severe Lung Disease. Int. J. Mol. Sci. 2017, 18, 1654. [CrossRef] [PubMed]
10. Everaerts, S.; Lagrou, K.; Vermeersch, K.; Dupont, L.; Vanaudenaerde, B.; Janssens, W. Aspergillus fumigatus
Detection and Risk Factors in Patients with COPD–Bronchiectasis Overlap. Int. J. Mol. Sci. 2018, 19, 523.
[CrossRef] [PubMed]
11. Máiz, L.; Nieto, R.; Cantón, R.; Gómez, G. de la Pedrosa, E.; Martinez-García, M. Fungi in Bronchiectasis:
A Concise Review. Int. J. Mol. Sci. 2018, 19, 142. [CrossRef] [PubMed]
12. Faverio, P.; Stainer, A.; Bonaiti, G.; Zucchetti, S.; Simonetta, E.; Lapadula, G.; Marruchella, A.; Gori, A.;
Blasi, F.; Codecasa, L.; et al. Characterizing Non-Tuberculous Mycobacteria Infection in Bronchiectasis. Int. J.
Mol. Sci. 2016, 17, 1913. [CrossRef] [PubMed]
13. Maselli, D.; Keyt, H.; Restrepo, M. Inhaled Antibiotic Therapy in Chronic Respiratory Diseases. Int. J.
Mol. Sci. 2017, 18, 1062. [CrossRef] [PubMed]
14. Miravitlles, M.; Anzueto, A. Chronic Respiratory Infection in Patients with Chronic Obstructive Pulmonary
Disease: What Is the Role of Antibiotics? Int. J. Mol. Sci. 2017, 18, 1344. [CrossRef] [PubMed]
15. Fastrès, A.; Felice, F.; Roels, E.; Moermans, C.; Corhay, J.; Bureau, F.; Louis, R.; Clercx, C.; Guiot, J. The Lung
Microbiome in Idiopathic Pulmonary Fibrosis: A Promising Approach for Targeted Therapies. Int. J. Mol. Sci.
2017, 18, 2735. [CrossRef] [PubMed]
16. Haworth, C.S.; Banks, J.; Capstick, T.; Fisher, A.; Gorsuch, T.; Laurenson, I.F.; Leitch, A.; Loebinger, M.R.;
Milburn, H.; Nightingale, M.; et al. British Thoracic Society Guideline for the management of nontuberculous
mycobacterial pulmonary disease (NTMPD). BMJ Open Resp. Res. 2017, 4, e000242. [CrossRef] [PubMed]
17. Wenzler, E.; Fraidenburg, D.R.; Scardina, T.; Danziger, L.H. Inhaled Antibiotics for Gram-Negative
Respiratory Infections. Clin. Microbiol. Rev. 2016, 29, 581–632. [CrossRef] [PubMed]
18. Smith, S.; Rowbotham, N.J.; Regan, K.H. Inhaled anti-pseudomonal antibiotics for long-term therapy in
cystic fibrosis. Cochrane Database Syst. Rev. 2018, 3. [CrossRef] [PubMed]
19. Polverino, E.; Goeminne, P.C.; McDonnell, M.J.; Aliberti, S.; Marshall, S.E.; Loebinger, M.R.; Murris, M.;
Cantón, R.; Torres, A.; Dimakou, K.; et al. European Respiratory Society guidelines for the management of
adult bronchiectasis. Eur. Respir. J. 2017, 50, 1700629. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2018, 19, 3051 6 of 6
20. FDA Approves a New Antibacterial Drug to Treat a Serious Lung Disease using a Novel Pathway to
Spur Innovation. Available online: https://www.fda.gov/newsevents/newsroom/pressannouncements/
ucm622048.htm (accessed on 30 September 2018).
21. Hewitt, R.J.; Molyneaux, P.L. The respiratory microbiome in idiopathic pulmonary fibrosis. Ann. Transl. Med.
2017, 5, 250. [CrossRef] [PubMed]
© 2018 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
